The Coronavirus Crisis: Challenges and Opportunities for CMOs, CDMOs and CROs
Experts Share Their Opinions on How the Custom Manufacturing and Research Industry can Tackle the Impact of the Covid-19 Pandemic and a Demanding Economic Climate
-
Foto: Getty Images 922950106 -
Michael Quirmbach, CEO & President, CordenPharma. © CordenPharma -
Peter Pekos, CEO, Dalton Pharma Services. © Dalton Pharma Services -
GianMarco Negrisoli, President Flamma USA, Flamma Group. © Flamma Group -
Jean-Luc Herbeaux, Chief Operating Officer, Hovione. © Hovione -
Andrew S. Thompson, President and CEO, J-Star. © J-Star -
David Zimmermann, Chief Executive Officer, Kalexsyn, and North America Sales Director, Dipharma. © Kalexsyn -
Alan E. Walker, Vice President Marketing & Development, Kaneka. © Kaneka -
Matthew Moorcroft, Global Head Central Marketing, Lonza. © Lonza -
Peter Halkjaer-Knudsen, Executive Vice President, Raybow Pharmaceuticals. © Raybow Pharmaceuticals -
Mark Quick, Executive Vice President Corporate Development, Recipharm. © Recipharm -
Andrew Henderson, Chief Commercial Officer, Sterling Pharma Solutions. © Sterling Pharma Solutions
The ongoing pandemic is putting pharmaceutical R&D strategies to the test and also challenging manufacturing planning and supply chain management. Particularly in this industry segment, the supply chain is global, complex and interconnected. Each link must be strong enough to ensure that the road from lab to final drug product is as smooth as possible, even under the most difficult circumstances.
In addition to the pandemic, the growing threat of a no-deal-Brexit amid old and new trade conflicts and increasing protectionism, is putting even more stress on companies operating in the pharma sector.
In cooperation with Wombat Capital*, a cross-border investment bank, CHEManager asked executives and experts of CMOs, CDMOs and CROs operating in the pharmaceutical sector to share their opinion on current challenges for their industry and how these challenges may influence changes in their market and opportunities.
Read the insightful answers of the experts here.
-
Expert Interview: Michael Quirmbach, CordenPharma
-
Expert Interview: Peter Pekos, Dalton Pharma Services
-
Expert Interview: GianMarco Negrisoli, Flamma
-
Expert Interview: Jean-Luc Herbeaux, Hovione
-
Expert Interview: Andrew Thompson, J-Star
-
Expert Interview: David Zimmermann, Kalexsyn
-
Expert Interview: Alan Walker, Kaneka
-
Expert Interview: Matthew Moorcroft, Lonza
-
Expert Interview: Peter Halkjaer-Knudsen, Raybow Pharmaceuticals
-
Expert Interview: Mark Quick, Recipharm
-
Expert Interview: Andrew Henderson, Sterling Pharma Solutions
* Cross-border investment bank Wombat Capital provides mergers and acquisitions and strategic advisory services. With offices in New York and Paris, Wombat Capital focuses on the CDMO/CRO and pharma outsourcing sectors.
